| Bioactivity | Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity[1]. |
| Target | AXL |
| Invitro | ADCT-601 (0.02-9.29 nM；5 天) 对 AXL 阳性 SN12C 细胞和 AXL 阴性 Karpas-299 细胞显示出细胞毒性[1]。ADCT-601 (0.83 nM；2-36 小时) 在 SN12C 细胞中时间依赖性地增加 DNA 链间交联水平[1]。 Cell Cytotoxicity Assay[1] Cell Line: |
| In Vivo | ADCT-601 (3 mg/kg、6 mg/kg；静脉注射；单剂量) 在非荷瘤雄性 Sprague-Dawley 大鼠中具有安全性和耐受性[1]。ADCT-601 (1 mg/kg；静脉注射；每天一次，持续 60 天) 在 MDA-MB-231 TNBC 异种移植模型和 SN12C 肾癌异种移植模型中均对小鼠显示出有效且持续的抗肿瘤活性[1]。ADCT-601 (0.075、0.15 或 0.3 mg/kg；静脉注射；每天一次，持续 45 天) 在具有异质 AXL 表达的胰腺癌 PDX 模型 (PAXF1657) 中也呈剂量依赖性[1]。 Animal Model: |
| Name | Mipasetamab |
| CAS | 2361055-48-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zammarchi F, et al. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. Mol Cancer Ther. 2022 Apr 1;21(4):582-593. |